Cereno Scientific to present preclinical data for drug candidates CS014 and CS585 at the 65th ASH Annual Meeting & Exposition 2023
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that two abstracts on the preclinical drug candidate CS014 and CS585, respectively, have been accepted and will be presented at the 65th ASH Annual Meeting & Exposition organized by the American Society of Hematology, in San Diego, US, on December 9-12, 2023.
The abstract titled “HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of Bleeding”, was authored by L. Stanger, M. Holinstat, S. Lambert and P. Yalavarthi at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US; B. Dahlöf and, N. Bergh at the University of Gothenburg, Gothenburg, Sweden. The abstract will be presented by Dr. Michael Holinstat, lead of Cereno’s development programs at the University of Michigan and Director of Translational Research at Cereno.
The abstract titled “CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists”, was authored by L. Stanger, P. Yalavarthi, S. Lambert, A. Rickenberg, K. Goerger and D. Gilmore at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US; B. Dahlöf and N. Bergh at the University of Gothenburg, Gothenburg, Sweden; and M. Holinstat at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US. The abstract has been awarded the ASH Abstract Achievement Award for being one of the top-scoring abstracts at the upcoming ASH meeting. The abstract will be presented by Livia Stanger at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US.
Details on the poster presentation of CS014:
Presentation Title: 1195 HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of Bleeding
Authors: L. Stanger, M. Holinstat, S. Lambert and P. Yalavarthi at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US; B. Dahlöf and, N. Bergh at the University of Gothenburg, Gothenburg, Sweden.
Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I
Hematology Disease Topics & Pathways: Fundamental Science, Research, Translational Research, Non-Biological therapies, drug development, Therapies, Pharmacology
Presentation Date: Saturday, December 9, 2023
Session Time: 17:30 - 19:30 PST
Details on the poster presentation of CS585:
Presentation Title: 1188 CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists
Authors: L. Stanger, P. Yalavarthi, S. Lambert, A. Rickenberg, K. Goerger, D. Gilmore at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US; B. Dahlöf and N. Bergh at the University of Gothenburg, Gothenburg, Sweden; and M. Holinstat at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US.
Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I
Hematology Disease Topics & Pathways: Research, Fundamental Science, Translational Research, Non-Biological therapies, drug development, Therapies, Pharmacology
Presentation Date: Friday, August 25, 2023.
Presentation Date: Saturday, December 9, 2023
Session Time: 17:30 - 19:30 PST
For further information, please contact:
Tove Bergenholt, Director IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 732-366 246
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q2 2024. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.